Articles related to ATRIAL FIBRILLATION (AFIB)

In the landscape of cardiac monitoring, consumer-grade smart devices have shown a remarkable ability to detect atrial fibrillation with high sensitivity and specificity, challenging the traditional reliance on medical-grade monitoring tools.

In this pivotal trial, apixaban, when used for subclinical atrial fibrillation, demonstrated a 0.63 hazard ratio for stroke or systemic embolism compared to aspirin, indicating a significant reduction in stroke risk at the expense of increased bleeding risk.

The study underscores the potential of user-owned devices in health monitoring. With a positive predictive value of 0.84, the smartwatch app could be a significant step towards large-scale, user-driven monitoring for atrial fibrillation.

Discover how catheter ablation combined with medical therapy can improve outcomes for atrial fibrillation patients with end-stage heart failure.

The study’s findings call for risk stratification and follow-up in patients with transient new-onset AF during hospitalization.

This study offers valuable insights into the comparative efficacy and safety of apixaban and rivaroxaban in obese patients with NVAF, highlighting the need for a patient-centered approach in anticoagulant selection.